It is intended to provide mutants of anti-CD40 antibody, which is expected as therapeutically efficacious, having been optimized as a drug by lowering the ADCC and CDC activities thereof. Namely, an agonistic anti-CD40 monoclonal antibody mutant in which at least the hinge region is a hinge region originating in human IgG2 and which has a mutation and/or a substitution of one or more amino acids causing lowering in the ADCC and/or CDC activities in the constant region; and an antagonistic anti-CD40 antibody mutant which has at least one mutation and/or substitution causing lowering in the ADCC and/or CDC activities in the constant region.
申请公布号
WO2005063981(A1)
申请公布日期
2005.07.14
申请号
WO2004JP19750
申请日期
2004.12.24
申请人
KIRIN BEER KABUSHIKI KAISHA;TAKAHASHI, NOBUAKI;MIURA, TORU;KITAGAWA, YOSHINORI;HIRANO, AKI
发明人
TAKAHASHI, NOBUAKI;MIURA, TORU;KITAGAWA, YOSHINORI;HIRANO, AKI